key: cord-0954159-s2duu8g2
authors: Damluji, Abdulla A.; Christenson, Robert H.; deFilippi, Christopher
title: Clinical Application of Serologic Testing for Coronavirus Disease 2019 in Contemporary Cardiovascular Practice
date: 2021-02-23
journal: J Am Heart Assoc
DOI: 10.1161/jaha.120.019506
sha: fe2feeda871d78af90e4810bf799fb8e5d7664f0
doc_id: 954159
cord_uid: s2duu8g2

In patients with cardiovascular disease, the use of antibody or serological testing is frequently encountered as the coronavirus disease 2019 pandemic continues to evolve. Antibody testing detects one form of the acquired immunological response to a pathogenic antigen. Once the immune system recognizes a viral antigen or a protein as foreign, a humoral immune response is initiated, which is generally detected by laboratory testing in 5 to 10 days after the initial exposure. While this information is critical from a public health perspective to implement surveillance systems and measures to limit infectivity and transmission rate, the misinterpretation of serologic testing in clinical practice has generated much confusion in the medical community because some attempted to apply these strategies to individual patient's treatment schemes. In this mini‐review, we examine the different serologic‐based testing strategies, how to interpret their results, and their public health impact at the population level, which are critical to contain the transmission of the virus in the community within a busy cardiovascular practice. Further, this review will also be particularly helpful as vaccination and immune therapy for coronavirus disease 2019 become available to the society as a whole.

T he World Health Organization declared coronavirus disease 2019 (COVID-19) a pandemic with millions of people infected resulting in substantial morbidity and mortality worldwide. Cardiovascular practitioners are now frequently asked to interpret the results from an array of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tests. Serologic testing in particular has been controversial with different strategies implemented in hospital-, office-, and community-based settings. In this mini-review, we critically appraise serologic-based testing and strategies for clinical and research applications.

Antibody (or serology) testing detects one form of the acquired immunological response to a pathogenic antigen. Serology depends on the immune system recognizing an antigen (typically a protein) as foreign and eliciting a humoral response, which is generally detectable 5 to 10 days after the infection. Although it is generally accepted that immunoglobulin M (IgM) is detectable after 5 to 10 days and immunoglobulin G (IgG) total antibody after 11 to 14 days, for anti-SARS-CoV-2, there is controversy about the sequence of antibody subtype response after acute COVID-19. 1 For example, Long et al reported that the median day of conversion for both IgM and IgG titers was 13 days, but 3 types of seroconversion were observed: (1) synchronous seroconversion of IgG and IgM; (2) IgM seroconversion earlier than that of IgG; and (3) IgM seroconversion later than that of IgG. 2 Because of the humoral response's delay, anti-SARS-CoV-2 testing is not useful for diagnosis of acute COVID-19. Rather, the indication for serologic testing includes: (1) understanding COVID-19 epidemiology; (2) assessing an individual's previous 

Anti-SARS-CoV-2 assays can evaluate for presence and quantity of IgG, IgM, IgA, or total antibody by "binding"; or "functional" assays, which can determine the presence of neutralizing antibodies. The foundation of anti-SARS-CoV-2 testing is binding assay detection of antibodies in a person's blood to one of several protein-antigens of SARS-CoV-2 including the nucleocapsid phosphoprotein, spike full-length protein, and receptor binding domain (RBD) (Figure 1 ). For measurement to be optimally informative, the binding assay must have high specificity for SARS-CoV-2 antibodies. The nucleocapsid protein is the virus' most abundant protein-antigen. 3 However, cross-reactivity with other coronaviruses is a concern. 3 The SARS-CoV-2 spike protein has been championed as a highly specific target because it deviates most among coronaviruses with a number of unique epitopes. The spike protein shares only 75% genome sequence identity with SARS-CoV and the similarity with the common cold coronaviruses spike proteins is only 50% to 60%. 3 Spike protein is critical in viral entry to the host cell by the receptorbinding domain of the S1 subunit of the spike protein. 4 Through the S2 subunit, fusing the virus to the host membrane occurs. 4 Therefore, the binding assays targeting RBD regions of the spike protein and their subunits (S1 and S2) may also have the closest association with the findings from functional assays measuring the presence of neutralizing antibodies. 4, 5 It should be noted that some "binding" assays are only qualitative, and the manufacturer may recommend that positive results must be confirmed with another method. Two general types of binding antibody tests are available that can detect total SARS-CoV-2 antibodies or specific subtypes (ie, IgG): (1) point-of-care lateral flow assays that bind antibodies in whole blood from a finger stick or venipuncture; or (2) manual or highly automated ELISA-type assays that provide results as a color, fluorescence or sensitive chemiluminescent signal that quantifies the amount of antigen-antibody complex formation directly or after serial dilution. Generally lateral flow tests perform poorly with respect to specificity compared with more quantitative measures making their use uncertain. 6 Currently no tests for anti-SARS-CoV-2 are Food and Drug Administration (FDA)-cleared (ie, meet stringency requirements of laboratory tests used in clinical practice like troponin), but a substantial number have received FDA Emergency Use Authorization.

Neutralization assays are in vitro methods that assess immunity to viral illness by quantifying functional anti-SARS-CoV-2 activity. ELISA are first performed by serial dilutions of the patient serum sample and values from the dilution curve are used to determine the area under the curve to quantify the anti-SARS-CoV-2 activity. 7 Figure 1 shows that neutralization tests are performed by incubating the patient sample with a live SARS-CoV-2 viral (or a pseudo-virus expressing SARS-CoV-2 proteins) suspension at serially diluted sample concentrations. The reported value is the greatest dilution at which antibody concentration is able to reduce the virus' infectivity in vitro by 50% PRNT 50 . Such levels of antibodies reflect the ability of the patient to neutralize viral activity. Functional neutralization assays are time consuming and not yet FDA approved.

The wide availability of serologic binding assays, their ability to rapidly detect an active immune response at a low-cost are characteristics that make them ideal for population screening and monitoring of immune response. An interactive example of longitudinal serosurveys and how they can be used to predict asymptomatic infection was recently published by the Centers for Disease Control and Prevention and can provide regional insights as to what to expect for positive viral testing before invasive cardiac procedures. To maximize the specificity to distinguish those with true positives, 3 testing strategies have been proposed. First, a single strategy test includes using a serologic test with high specificity ≥95%, which results in acceptable positive predictive value, but it is challenged when there is a low population prevalence of prior exposure. Second, test only those with a high pre-test probability of COVID-19. Third, an orthogonal test strategy includes an initial serologic-based test and among those who test positive, a second test for antibodies to a different viral epitope is subsequently performed. Orthogonal testing strategies are used to achieve maximum specificity while retaining high sensitivity. 8 Antibody testing turns positive 5 to 10 days after exposure but remains positive for months or years after

Coronavirus Disease 2019 FDA Food and Drug Administration SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 initial infection. This information is useful for public health monitoring, as previously expressed, because the orthogonal testing strategy is highly sensitive for population transmission. Global immunological observatory or surveillance systems to detect signals of infection on a population level and related seasonality can limit the transmission of the virus in the community. Because viral or molecular testing remains positive in an infected individual for only a short period of time, testing at infrequent intervals from the population level can result in an underestimation of the point prevalence of COVID-19. However, the use of serologic testing in a population at risk may allow a more accurate assessment of the point prevalence because the viral antibodies remain detectable in the blood for months or potentially years after the initial exposure. From a cost perspective, serologic testing is much cheaper than molecular testing, which is particularly relevant when large segments of the population are being tested. Combing the information obtained from molecular and serologic testing together from one population at risk can also be helpful to contain the COVID-19

infection. For example, estimates on a point prevalence of 4% based molecular testing combined with high estimates from serologic testing can potentially mean that the infection is likely decreasing in the population as a whole because the population had already developed an immune response to the virus (ie, had a prior infection). However, a similar point prevalence of 4% based on molecular testing combined with low estimates of infection based on serologic testing in the population at risk can potentially mean that the infection will rise in the near future because the population at risk had not been previously exposed to the virus, and more public health measures should be implemented to limit the infectivity and transmission rates in the community as a whole.

The burden and clinical implication of COVID-19 on the society as a whole remains substantial, but the prevalence of the disease is variable depending on The figure illustrates the protein antigens of the severe acute respiratory syndrome coronavirus 2: nucleocapsid phosphoprotein, spike full-length protein, and receptor binding domain and the 2 most common serology-based testing strategies: enzyme-linked immunosorbent assay and chemiluminescent immunoassay. PRNT 50 indicates 50% plaque reduction neutralization test; and SARS-COV-2, severe acute respiratory syndrome coronavirus 2. The nucleocapsid protein is not shown in the illustration because it is attached to the viral RNA. The illustration only shows the surface proteins; the orange proteins represent the phospholipid bilayer. The blue/purple 5-part proteins represent viroporin pentamers, also called E proteins. exposure and transmission rates within different regions of the United States. In large areas with low disease prevalence, the Centers for Disease Control and Prevention recommends a 2-stage specimen pooling strategy, or orthogonal testing for population surveillance. 9 According to the Centers for Disease Control and Prevention, Public Health surveillance is an "ongoing systematic collection, analysis, and interpretation of health-related data essential for planning implementation, and evaluation of public health practice, closely integrated with the timely dissemination of these data to those responsible for prevention and control". 10 This surveillance system is important because it (1) evaluates the overall public health status of a communicable disease; (2) defines priorities where public health interventions are needed; (3) evaluates the effectiveness of public health programs (eg, vaccinations and immune therapies); and (4) serves as a pivot for future research. 10 When 2 orthogonal testing strategies are used in the community with low prevalence of COVID-19, the positive predictive value of the test is maximized ( Figure 2 ). The use of orthogonal testing strategies will further preserve resources, reduce the amount of time and effort aimed at obtaining a large number of specimens, and limit overall testing cost. 9

While some parts of the world are recovering from the effects of the pandemic, the United States and Europe are facing a large number of COVID-19 cases. Among the survivals, the long-term immune response to the virus remain an area of active investigation. Early reports indicated that among asymptomatic patients or those with mild symptoms, there was an immune signal at 3-months after onset of symptoms. [11] [12] [13] [14] The immune response with anti-SARS-CoV-2 spike and nucleocapsid IgG levels correlated with the neutralization titers during follow-up (Table) . 12 However, more recent data on the sustainability of the immune response after the onset of symptoms were contradictory. [15] [16] [17] Long et al showed that there was a median percentage decrease of 71.1% in IgG levels 2 months after the onset of illness, 2 and this finding was recently corroborated by other studies. 17, 18 Other investigators reported sustained IgM and IgG levels in symptomatic participants against spike RBD, S2, with these neutralizing antibodies remaining detectable 5 to 7 months after the onset of symptoms (Table) . This gap in knowledge has critical implications on vaccination development and immunotherapies to limit the spread of the virus. Longer term data on sustainability of serologic response to SARS-CoV-2 will be necessary to evaluate the efficacy of immune therapies in the society as a whole.

Walsh et al have reported on the safety and immunogenicity of 2 mRNA-based COVID-19 vaccine candidates. 26 To increase immunogenicity, the BNT162b1 that encodes the SARS-CoV-2 RBD was trimerized by adding T4 fibritin foldon domain. The BNT162b2 that encodes the SARS-CoV-2 full-length spike protein was modified by 2 proline mutations. 26, 27 Both vaccine candidates had similar immunologic response with antigen-antibody binding and neutralizing antibodies. 26 The highest 90% neutralization titers were observed 7 or 14 days after the second dose elicited by BNT162b1 and BNT162b2. 26 The BNT162b2 was moved forward into a phase 2/3 clinical trial and now had FDA emergency use authorization (Pfizer/ Biontech). The Moderna COVID-19 vaccine also received emergency use authorization by the FDA. This vaccine uses the virus's mRNA, which instructs the human cells to produce copies of the spike protein and immune response against SARS-CoV-2. 28 Among participants who were between ages 56 to 70 years and those >70 years, the pseudovirus neutralization assay showed that the 50% inhibitory dilution was the highest at 43 days when 100-μg dose of the mRNA-1273 was administered. 28 These vaccination programs appear to have excellent efficacy with antibody titers, which is typically 100-fold greater than convalescent plasma with associated greater neutralization capability and an acceptable safety profile. Therefore, with either of these vaccines at least early after administration, one would expect titers 100-fold higher than those who have had native infections. The durability of these titers after several months and what this indicates for immunity remains to be determined. Because these programs illicit immunologic response against the RBD and full-length spike protein, immunologic testing against the nucleocapsid may have an important role as orthogonal test for sero-surveys of the population to determine if infections still take place and could reflect a warning of mutation against the first generation of vaccine-produced antibodies. Lastly, recent preliminary evidence associated with the use of monoclonal antibody treatment in symptomatic ambulatory patients diagnosed with COVID-19, identified that the absence of endogenous serum antibodies to SARS-CoV-2 (negative to both IgG and IgA anti-S1 domain of the spike protein, and IgG anti-nucleocapsid protein), but not the time after the onset of symptoms (all treated within 7 days), as critical to identifying patients who had a significant drop in viral loads and reduced medical encounters versus symptomatic patients with measurable serum antibodies. 29 Whether serology studies should be evaluated before the administration of monoclonal antibodies, an expensive and limited resource, will need to be determined in a larger study. [19] [20] [21] [22] [23] [24] [25] 

The Centers for Disease Control and Prevention has stated "Serologic testing by itself should not be used to establish the presence or absence of SARS-CoV-2 infection or reinfection". Antibodies may not be present among those tested early in illness before antibodies develop or among those who never develop detectable antibodies following infection. In addition, the presence of antibodies may reflect previous infection and may be unrelated to the current illness. It is therefore important to recognize while knowledge continues to evolve that the presence or absence of detectable antibodies to SARS-CoV-2 can't be used as a surrogate to determine if a patient is potentially infectious for COVID-19 and this needs to be determined by molecular tests to detect the virus. Despite wide availability and relatively rapid turnaround of the test results, assessment of the exact levels of antibody needed to elicit a protective immune response with neutralization ability remains unknown. Many antibody assays are available and the FDA's approval by Emergency Use Authorization means assessment isn't nearly as rigorous as the typical 510k process. Cross-reactivity with other respiratory viral pathogens can result in false-positive results, but these can be overcome with orthogonal testing strategies. Generally large instrument in-vitro diagnostic manufacturers have created serology assays with high sensitivity and specificity. Finally, the heterogeneity of the immune response and waning of immunity with time that can be tracked with serology assays are fundamental issues that will influence the development of therapies, including vaccines, aimed to modulate the immune response to SARS-CoV-2 infection. 3

Understanding the clinical implications for serologic testing are critical for cardiovascular practice in the near future as vaccination and immune therapy for COVID-19 become available in clinical practice. This in turn will affect how we manage the urgent and perhaps even eventually the elective care of cardiovascular patients. Many serologic assays that received FDA Emergency Use Authorization can be used to detect previous infections with COVID-19 by detecting the acquired immune response to SARS-CoV-2, but conflicting data exist on the sustainability of this immune response to the virus. In current cardiovascular practice, antibody-binding tests with high specificity ≥95% can provide insights into the regional probability of positive molecular tests for SARS-CoV-2 infection in patients undergoing cardiovascular procedures. Further research is needed to determine if a positive serology result in asymptomatic patients should trigger an evaluation for subclinical SARS-CoV-2 induced cardiovascular disease.

Received November 2, 2020; accepted January 6, 2021. 

Serology testing in the covid-19 pandemic response

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Developing antibody tests for SARS-CoV-2

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Serology for SARS-CoV-2: apprehensions, opportunities, and the path forward

Diagnostic accuracy of serological tests for covid-19: systematic review and metaanalysis

A serological assay to detect SARS-CoV-2 seroconversion in humans

Current Status of Antibody Testing in the United States. Available at

Interim Guidance for Use of Pooling Procedures in SARS-CoV-2

Hospital-wide SARS-CoV-2 antibody screening in 3056 staff in a tertiary center in Belgium

Kinetics of viral load and antibody response in relation to COVID-19 severity

SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. medRxiv

Functional SARS-CoV-2-specific immune memory persists after mild COVID-19

Humoral immune response to SARS-CoV-2 in Iceland

Change in antibodies to SARS-CoV-2 over 60 days among health care personnel in

Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19

Loss of anti-SARS-CoV-2 antibodies in mild Covid-19

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic covid-19. medRxiv

Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19: prospective cohort study

Immunological memory to SARS-CoV-2 assessed for greater than six months after infection

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults

REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19

The authors acknowledge Ms. Devon Stuart for her assistance with medical illustrations.